The TEAD2 antibody is a crucial tool for studying the TEAD family of transcription factors, which includes four members (TEAD1-4) involved in regulating genes essential for development, cell proliferation, and organ growth. TEAD proteins bind DNA via a conserved TEA domain and require co-activators like YAP/TAZ (Hippo pathway effectors) to modulate transcriptional activity. TEAD2. specifically, is implicated in embryonic development, stem cell maintenance, and cancer progression, with dysregulation linked to tumors such as glioblastoma and melanoma.
Antibodies targeting TEAD2 enable researchers to detect and quantify its expression, localization, and interactions in various experimental models. These antibodies are typically developed in immunized hosts (e.g., rabbits, mice) using immunogens derived from TEAD2-specific epitopes, often validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). Specificity is confirmed through knockout/knockdown controls or peptide blocking assays.
Commercial TEAD2 antibodies often include validation data (e.g., reactivity in human/mouse samples, molecular weight ~50 kDa) and are critical for exploring TEAD2’s role in Hippo signaling, cancer mechanisms, and regenerative medicine. Researchers prioritize antibodies with low cross-reactivity to other TEAD paralogs to ensure accurate results.